Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. - Wikidata - wikimedia - TriplyDB

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.

http://www.wikidata.org/entity/Q44370286

about

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Unexplained anemia in the elderly Therapeutic Strategies for Neuropathic Pain: Potential Application of Pharmacosynthetics and Optogenetics The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients Pomalidomide is active in the treatment of anemia associated with myelofibrosis Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Choosing between stem cell therapy and drugs in myelofibrosis.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Lenalidomide in the treatment of multiple myeloma: a review.Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.Lenalidomide in the treatment of chronic lymphocytic leukemia.Properties of thalidomide and its analogues: implications for anticancer therapy.Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.Thalidomide and its analogues in the treatment of Multiple Myeloma CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.Combination immune therapies to enhance anti-tumor responses by NK cells.Cost-effectiveness of lenalidomide in multiple myeloma.Drug-mediated and cellular immunotherapy in multiple myeloma.Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.

P2860

Q21285161-B3B3ED67-5017-4326-8C1B-6ABF8B4B3AEC Q24605861-43E8ED76-71E8-41AE-BA59-209F976F2A8A Q24654893-CB627E9F-5695-4C2B-97B9-FF0FEF5BDFAC Q26765373-8E4A7362-4134-45C8-9784-03BCC953B507 Q26771431-B6EF571A-DC0F-4733-A638-CD2CD65FBC8F Q26822754-DF8B62BC-7B6F-4B93-8B1E-52CB94128270 Q28534976-5349E515-EE83-44FC-B53A-2D0E17A0D6F6 Q33385644-03C2B539-2864-44A9-B595-E302116754C5 Q33386057-BC82E172-F044-4A70-8898-B367BE5D6781 Q33408049-C9C24A84-5FAD-476E-9DBD-1A2598FE47F1 Q33408279-C640A05E-61B1-493B-ABE8-2DD43045D179 Q33410022-F8B46999-1D4D-4EDB-9181-7381737F7EBC Q33413210-24ED4F27-773A-4C8F-9E78-A116B2EF376E Q34253548-1744E7C7-A1B1-4512-829D-A7E897A3C5C7 Q34314074-F5241354-A07A-4B43-835C-4412698AA20B Q34342944-DAF1E73E-A98A-4023-81B6-22F344275467 Q34541542-B296878A-FAF1-47BB-AFEE-F2CC19D5AC54 Q34734491-D7FB49BD-CC02-44E5-828A-262D8C68E8D6 Q34775475-DEEC8986-7510-48A9-9058-9F7BF7799503 Q34775515-F2296110-AF39-4F3F-A1B7-38E575A56F82 Q35064910-F868AE67-9F2D-4A46-93B3-87F805C0269E Q35171777-25EEB432-E17F-4451-BAA0-3CFDE1EF8E72 Q35608564-991F1C6F-05DF-4EDD-8536-7AFFBBBD08AF Q35641782-0FAD25D0-F473-4B79-952C-E9C192EBF351 Q35784505-BA08E65A-38E3-491E-B5B0-65FF4424C450 Q36018407-2BEA72D0-DB1D-4070-895C-D2AD1EEE8ACC Q36125070-8854A048-1641-47D6-A9A6-07CF91678B41 Q36250757-EF1B81BA-1758-4B73-B592-18F7BAF84D4A Q36274133-CADD3157-15E4-4B7E-BE38-5EAD3A5E37D4 Q36364976-57C68D0C-5268-4238-894E-5B58D2F70CC6 Q36444523-834F5F11-9763-4A0F-8607-347318F2B33C Q36546548-9910FD4E-A94C-432C-9A97-806158B2C64C Q36806619-CD11B768-FDA2-4CC2-B9F0-C195012A9F14 Q36920412-6575BD14-E0DA-4140-87B7-4D830273DF19 Q36965455-75C78B03-3AE2-404B-B822-C0A9279A71D2 Q37280938-98854732-0EA0-48C5-B94F-FB90AA5594D9 Q37408550-9C305E23-4379-4924-8B25-A3CC79E2F309 Q37764870-341132CC-7195-4EFA-887F-7E472AB2B84D Q37773257-2A911203-E0BA-43AC-8B05-95E06686FD0B Q37799831-DAB6CE78-362D-4163-813D-D6E5283A16AB

P2860

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.

http://www.wikidata.org/entity/Q44370286

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@en

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@nl

type

label

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@en

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@nl

prefLabel

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@en

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@nl

P1433

Q44370286-67904E90-6A14-47B7-8338-18D5BA3A09A8

P1476

Q44370286-E2838D41-24D4-4641-B7DF-CB2D80018A11

P2093

Q44370286-0F629B36-9D02-4ED2-AE8B-986D903DEE7A

Q44370286-2CF982F4-CA97-4F6E-ABAB-50429232CEEF

Q44370286-3A9DC78B-3986-4A31-B99D-C39B210FFD37

Q44370286-3DD4CCFA-3921-4AAE-923D-7D966FB8C837

Q44370286-622EC95A-C1F5-4590-BD5D-0F9570101220

Q44370286-81B264DF-34F7-4998-8E27-39CDEB5930E6

Q44370286-92DCA2F7-6332-4F37-8F3A-D5D4AB6E49B3

Q44370286-BB2F50C4-7C40-4398-88EB-799E443DD96B

Q44370286-CA1568A3-AE22-4684-80CF-B28E79E74576

Q44370286-EE315080-ED3A-42BA-B044-721DAB815F2C

P304

Q44370286-28016E8F-D832-4365-8097-88F84703156B

P31

Q44370286-84F78456-DE13-4DF0-8621-5A77FE8F937D

P356

Q44370286-8287A589-A14E-4697-B61B-5B2977C74EEA

P407

Q44370286-B3AFFFBC-59C2-4EAF-990C-8B09222C257A

P433

Q44370286-D58C4FEF-2A2F-4BBA-AA30-99B7D18E2637

P478

Q44370286-703D7775-D99A-4C4D-8884-7AF430CB65D2

P50

Q44370286-6c8490a0-4864-a015-eb4a-0425e52d341d

P577

Q44370286-30DD9B4D-1DA9-441D-BE28-0919D859F0A9

P5875

Q44370286-5BE9A7A4-6C52-43EA-BA1C-DFEC8CD2BFF4

P698

Q44370286-5BA9ED6A-D981-48B3-8159-341C88EF0156

P921

Q44370286-84023DCF-BC27-4FF8-A12C-B82AB16B9BCF

P356

JPET.102.048496

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Enhancement of cytokine produc ...... elated immunomodulatory drugs.

@en

P2093

Anita K Gandhi

http://www.w3.org/2001/XMLSchema#string

David I Stirling

http://www.w3.org/2001/XMLSchema#string

Faribourz Payvandi

http://www.w3.org/2001/XMLSchema#string

George W Muller

http://www.w3.org/2001/XMLSchema#string

Hon-Wah Man

http://www.w3.org/2001/XMLSchema#string

Laura G Corral

http://www.w3.org/2001/XMLSchema#string

Michelle A Loveland

http://www.w3.org/2001/XMLSchema#string

Paul P M Schnetkamp

http://www.w3.org/2001/XMLSchema#string

Peter H Schafer

http://www.w3.org/2001/XMLSchema#string

Roger S Chen

http://www.w3.org/2001/XMLSchema#string

P304

1222-1232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.102.048496

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

305

http://www.w3.org/2001/XMLSchema#string

P50

Gregor Wolbring

P577

2003-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10845813

http://www.w3.org/2001/XMLSchema#string

P698

12649301

http://www.w3.org/2001/XMLSchema#string

P921